Diaceutics PLC (DXRX.L) LSE
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
Diaceutics PLC
Address
Building Two
Belfast, AT BT9 6GW
United Kingdom of Great Britain and Northern Ireland (the)
Phone
+44 28 9031 3166
Website
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
184
First IPO Date
March 21, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Ryan Keeling | Chief Executive Officer & Director | 358,401 | 1982 |
| Peter Keeling | Founder & Non-Executive Chairman | 126,000 | 1960 |
| Jordan Clark | Chief Data Officer? & Executive Director | 243,517 | 1984 |
| Nicholas Stewart Roberts | Chief Financial Officer, Secretary & Director | 248,717 | 1982 |
| Sandra Blake | Chief People Officer | 0 | N/A |
| Ken Ruppel | Vice President of Scientific & Medical Services | 0 | N/A |
| Kerri Donaldson | Vice President of Operations | 0 | N/A |
| Madeline Brown | Vice President & Chief of Staff | 0 | N/A |
| Marianna Sciortino | Vice President of Sales | 0 | N/A |
| Lauren DeWitt | Executive Vice President of Legal, General Counsel & Group Company Secretary | 0 | N/A |
| Susanne Munksted | Chief Precision Medicine Officer | 0 | N/A |
| Amie McNiece | Vice President of Marketing | 0 | N/A |
Description
Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is a company dedicated to accelerating the commercialization of diagnostic solutions. It offers global pharmaceutical companies comprehensive data, advanced analytics, and implementation support. Central to its operations is the DXRX platform. This platform features DXRX data solutions, providing access to extensive diagnostic testing data pipelines from a broad network of laboratories, including real-time DXRX signal alerts, lab and physician mapping, and a testing dashboard. The DXRX platform also hosts a marketplace where laboratories, pharmaceutical firms, and diagnostic companies can connect to collaborate on precision medicine diagnostics. Diaceutics further provides DXRX Patient Journey, a tool for pharmaceutical clients to conduct detailed longitudinal analyses of individual patient biomarker testing paths, helping identify opportunities for earlier intervention and treatment. DXRX Lab Benchmarking allows laboratories to sharpen their competitive edge by comparing their key criteria against industry counterparts, encompassing metrics such as disease focus, testing methodologies, market share, turnaround times, and their standing as leaders in specific diagnostic fields. The DXRX Test Reimbursement service assists pharma clients in funding novel companion diagnostics, thereby shortening the time required for their widespread adoption. Furthermore, DXRX Test Signal delivers immediate notifications of testing events, empowering pharmaceutical clients to swiftly identify therapeutically actionable patients. Beyond the platform, Diaceutics furnishes services for diagnostic landscape analysis, strategic planning, implementation, and ongoing tracking, alongside expert consulting tailored to precision medicine diagnostics. Its extensive service portfolio also covers test standardization, quality evaluations, optimization of test reports, technical laboratory support, assistance with test access and reimbursement, laboratory training, and various educational resources.
